These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Apraxia of eyelid opening after subthalamic deep brain stimulation may be caused by reduction of levodopa. Umemura A; Toyoda T; Yamamoto K; Oka Y; Ishii F; Yamada K Parkinsonism Relat Disord; 2008 Dec; 14(8):655-7. PubMed ID: 18316231 [TBL] [Abstract][Full Text] [Related]
24. Impaired activity of the supplementary motor area in akinetic patients with Parkinson's disease. Improvement by the dopamine agonist apomorphine. Rascol OJ; Sabatini U; Chollet F; Montastruc JL; Marc-Vergnes JP; Rascol A Adv Neurol; 1993; 60():419-21. PubMed ID: 8420165 [No Abstract] [Full Text] [Related]
26. Correlation between acoustic speech characteristics and non-speech motor performance in Parkinson Disease. Goberman AM Med Sci Monit; 2005 Mar; 11(3):CR109-16. PubMed ID: 15735562 [TBL] [Abstract][Full Text] [Related]
27. Is decreased dexterity in Parkinson disease due to apraxia? Landau WM; Mink JW Neurology; 2007 Jan; 68(2):90-1. PubMed ID: 17210888 [No Abstract] [Full Text] [Related]
29. The apraxias are higher-order defects of sensorimotor integration. Marsden CD Novartis Found Symp; 1998; 218():308-25; discussion 326-31. PubMed ID: 9949828 [TBL] [Abstract][Full Text] [Related]
31. Axial versus distal motor impairment in Parkinson's disease. Weinrich M; Koch K; Garcia F; Angel RW Neurology; 1988 Apr; 38(4):540-5. PubMed ID: 3352908 [TBL] [Abstract][Full Text] [Related]
32. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL; CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687 [TBL] [Abstract][Full Text] [Related]
33. Effects of Stochastic Vestibular Galvanic Stimulation and LDOPA on Balance and Motor Symptoms in Patients With Parkinson's Disease. Samoudi G; JivegÄrd M; Mulavara AP; Bergquist F Brain Stimul; 2015; 8(3):474-80. PubMed ID: 25573070 [TBL] [Abstract][Full Text] [Related]
35. Therapeutic strategies to prevent motor complications in Parkinson's disease. Kieburtz K J Neurol; 2008 Aug; 255 Suppl 4():42-5. PubMed ID: 18821085 [TBL] [Abstract][Full Text] [Related]
36. Limb apraxia in corticobasal degeneration and progressive supranuclear palsy. Soliveri P; Piacentini S; Girotti F Neurology; 2005 Feb; 64(3):448-53. PubMed ID: 15699373 [TBL] [Abstract][Full Text] [Related]
37. Normal activation of the supplementary motor area in patients with Parkinson's disease undergoing long-term treatment with levodopa. Rascol O; Sabatini U; Chollet F; Fabre N; Senard JM; Montastruc JL; Celsis P; Marc-Vergnes JP; Rascol A J Neurol Neurosurg Psychiatry; 1994 May; 57(5):567-71. PubMed ID: 8201325 [TBL] [Abstract][Full Text] [Related]
38. Apraxia contributes to the motor deficit in Parkinson's Disease and multiple system atrophy. Swash M Eur J Neurol; 2010 Mar; 17(3):346-7. PubMed ID: 20050895 [No Abstract] [Full Text] [Related]
39. Exploring the relationship between motor impairment, vascular burden and cognition in Parkinson's disease. Stojkovic T; Stefanova E; Soldatovic I; Markovic V; Stankovic I; Petrovic I; Agosta F; Galantucci S; Filippi M; Kostic V J Neurol; 2018 Jun; 265(6):1320-1327. PubMed ID: 29572571 [TBL] [Abstract][Full Text] [Related]
40. Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson's disease. Merello M; Lees AJ J Neurol Neurosurg Psychiatry; 1992 Nov; 55(11):1024-6. PubMed ID: 1469397 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]